company background image
0MGB logo

Genmab LSE:0MGB Stock Report

Last Price

kr.2.08k

Market Cap

kr.135.9b

7D

2.0%

1Y

-18.9%

Updated

28 Mar, 2024

Data

Company Financials +

0MGB Stock Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.

0MGB fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Genmab A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Genmab
Historical stock prices
Current Share Pricekr.2,084.42
52 Week Highkr.2,946.00
52 Week Lowkr.1,824.50
Beta0.76
1 Month Change5.64%
3 Month Change-2.69%
1 Year Change-18.90%
3 Year Change-0.12%
5 Year Change77.32%
Change since IPO507.28%

Recent News & Updates

Recent updates

Shareholder Returns

0MGBGB BiotechsGB Market
7D2.0%1.7%2.2%
1Y-18.9%-27.5%3.7%

Return vs Industry: 0MGB exceeded the UK Biotechs industry which returned -27.5% over the past year.

Return vs Market: 0MGB underperformed the UK Market which returned 3.7% over the past year.

Price Volatility

Is 0MGB's price volatile compared to industry and market?
0MGB volatility
0MGB Average Weekly Movement4.6%
Biotechs Industry Average Movement7.9%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0MGB has not had significant price volatility in the past 3 months.

Volatility Over Time: 0MGB's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19992,204Jan G.J. van Winkelhttps://www.genmab.com

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.

Genmab A/S Fundamentals Summary

How do Genmab's earnings and revenue compare to its market cap?
0MGB fundamental statistics
Market capkr.135.86b
Earnings (TTM)kr.4.35b
Revenue (TTM)kr.16.47b

31.2x

P/E Ratio

8.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0MGB income statement (TTM)
Revenuekr.16.47b
Cost of Revenuekr.226.00m
Gross Profitkr.16.25b
Other Expenseskr.11.90b
Earningskr.4.35b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)66.76
Gross Margin98.63%
Net Profit Margin26.42%
Debt/Equity Ratio0%

How did 0MGB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.